Welcome to our dedicated page for Veradermics SEC filings (Ticker: MANE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Veradermics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Veradermics's regulatory disclosures and financial reporting.
Veradermics, Inc (MANE) had an initial statement of beneficial ownership filed for David Hollander, who serves as Chief R&D Officer. The filing reports no transactions and no beneficial ownership positions in Veradermics securities as of the reporting date.
Veradermics, Inc. (MANE) is the issuer of common stock that Averill Master Fund, Ltd., an affiliate, has filed to sell under Rule 144. The notice covers up to 690,601 shares of common stock, to be sold through BofA Securities, Inc. as broker on the NYSE. The shares were acquired from Veradermics upon conversion of Series B Preferred Stock, which was obtained on November 25, 2024 and converted on February 5, 2026. No other Rule 144 sales by this seller are listed for the prior three months.
Veradermics, Inc (MANE) reported that its Chief Technical Officer, Timothy August Durso, exercised stock options for 3,452 shares of Common Stock at an exercise price of $12.19 per share and on the same date sold an aggregate of 43,500 Common shares in multiple open-market transactions at weighted average prices ranging from about $106.71 to $111.28 per share. The option was fully vested and exercisable, and the transactions were made pursuant to a Rule 10b5-1 trading plan.
Veradermics, Inc (MANE) reported insider activity by Chief Executive Officer Reid Alexander Waldman. On 2026-08-17 he exercised 3,452 stock options to acquire an equal number of common shares at an exercise price of $12.19 per share from a fully vested option. On the same date, he reported open-market sales totaling 67,500 common shares in multiple tranches at reported weighted-average prices between $106.07 and $111.28 per share, executed pursuant to a Rule 10b5-1 trading plan.
MANE has a planned resale of restricted securities under Form 144. The filing lists up to 87,000 shares of common stock to be sold through J.P. Morgan Securities LLC on the NYSE, with a proposed sale date of August 17, 2026.
The 87,000 shares are composed of 3,452 shares associated with stock options originally dated March 24, 2020, and 83,548 founder shares from the same date. These are sales by an existing holder, not a new issuance by the company.
MANE has filed a notice of proposed sale of 135,000 shares of common stock under Form 144. The filing lists an aggregate market value of $15,022,800 for these shares and shows 41,780,136 shares outstanding as of 08/17/2026 on the NYSE.
The 135,000 shares consist of 3,452 shares acquired through a stock option and 131,548 founder shares, both originally acquired from the issuer. No sales of these securities are reported during the past three months.
Veradermics, Inc. shareholder SR One–affiliated funds amended their beneficial ownership report after selling shares in a private transaction. On August 12, 2026, SR One Capital Fund II Aggregator and AMZL sold an aggregate of 321,749 Veradermics common shares at $104.30 per share, for total consideration of approximately $33,558,420. After the sale, SR One Capital Fund II Aggregator holds 1,403,959 shares and AMZL holds 676,160 shares, for a combined total of 2,080,119 shares, representing 4.9% of Veradermics’ common stock outstanding based on 41,780,136 shares reported as of August 6, 2026. The reporting persons state they have no current plans regarding control-related actions involving Veradermics but note the funds may dispose of additional shares depending on market conditions. As of August 12, 2026, each reporting person has ceased to beneficially own 5% or more of the issuer’s common stock.
Glen Eagle Wealth LLC plans to sell up to 100,000 shares of MANE common stock, with an aggregate market value of $10,905,000, under a planned sale date of August 12, 2026 on the NYSE. The filing also lists 41,780,136 shares of MANE common stock outstanding. In addition, it notes that 294,117 shares of common stock were sold for cash on February 5, 2026 through an IPO underwriter during the past three months.
Entities associated with Veradermics, Inc director John W. Childs reported selling a total of 100,000 shares of Veradermics common stock on August 12, 2026. The shares were held indirectly through the John W. Childs 2013 Revocable Trust and J.W. Childs Associates (FL), L.P., with prices based on weighted-average sale ranges.